IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: HILLMAN=1 In re Application of: Conf. No.: 9264 Yitzchak HILLMAN Art Unit: 1645 Appln. No: 10/539,558 Examiner: Filed: June 17, 2003 Washington, D.C. DIŚEASE TREATMENT VIA November 29, 2006 For: ANTIMICROBIAL PEPTIDE...

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:
- [] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

In re Appln. No. 10/539,558

- [X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.
- [X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [X] 4. Other information being provided for the examiner's consideration follows:

INTERNATIONAL SEARCH REPORT

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:

Amne M. Kornbau

Registration No. 25,884


AMK:srd

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202) 628-5197

Facsimile: (202)737-3528 G:\BN\B\BENA\Hillman1\pto\2006-11-29 IDS.doc



INFORMATION	I DISCLOSURE
STATEMENT E	SY APPLICANT

(use as many sheets as necessary)

of

Sheet

Complete if Known		
Application Number	10/539,558	
Filing Date	June 17, 2003	
First Named Inventor	Yitzchak HILLMAN	
Group Art Unit	1645	
Examiner Name		
Attorney Docket Number	HILLMAN=1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-2002/0072495 A1	06-13-2002	CHERTOV et al.	
	AB	US-6,335,318 B1	01-01-2002	SELSTED et al.	
		US-			
		US-	,		
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	of Cited Desument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	AC	WO 9807833 A1	02-26-1998	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA MAGANIN PHARMACEUTICALS, INC		

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.